NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.62
+0.28 (2.47%)
At close: Aug 13, 2025, 4:00 PM
11.51
-0.11 (-0.95%)
Pre-market: Aug 14, 2025, 9:04 AM EDT
NovoCure Revenue
NovoCure had revenue of $158.81M in the quarter ending June 30, 2025, with 5.62% growth. This brings the company's revenue in the last twelve months to $630.16M, up 14.58% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$630.16M
Revenue Growth
+14.58%
P/S Ratio
2.02
Revenue / Employee
$423,495
Employees
1,488
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVCR News
- 15 days ago - NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha
- 17 days ago - Top 3 Health Care Stocks That May Explode In July - Benzinga
- 19 days ago - NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Novocure Reports Second Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 - Business Wire
- 6 weeks ago - Novocure to Report Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 2 months ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire